

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 November 2023 (09.11.2023)



(10) International Publication Number
WO 2023/215220 A1

(51) International Patent Classification:

C07D 285/00 (2006.01) A61P 1/16 (2006.01)
C07D 291/08 (2006.01) C07D 515/04 (2006.01)
C07D 498/08 (2006.01) C07D 515/08 (2006.01)
C07D 513/08 (2006.01) A61K 31/395 (2006.01)

(21) International Application Number:

PCT/US2023/020546

(22) International Filing Date:

01 May 2023 (01.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/337,344 02 May 2022 (02.05.2022) US
63/481,045 23 January 2023 (23.01.2023) US

(71) Applicant: **ESPERION THERAPEUTICS, INC.**
[US/US]; 3891 Ranchero Drive, Suite 150, Ann Arbor,
Michigan 48108 (US).

(72) Inventors: **PINKOSKY, Stephen Lawrence**; 1351 Hart-
sough Street, Plymouth, Michigan 48170 (US). **DAVEN-
PORT, Adam James**; 114 Innovation Drive, Milton Park,
Abingdon Oxfordshire OX14 4RZ (GB). **GLEAVE, Lau-
ra Jane**; 114 Innovation Drive, Milton Park, Abingdon Ox-
fordshire OX14 4RZ (GB). **SOUTHEY, Michelle Wing
Yan**; 114 Innovation Drive, Milton Park, Abingdon Ox-
fordshire OX14 4RZ (GB). **URSINYOVA, Nina Connel-
ly**; 114 Innovation Drive, Milton Park, Abingdon Oxford-
shire OX14 4RZ (GB). **WALKER, Patrick Ross**; 114 In-
novation Drive, Milton Park, Abingdon Oxfordshire OX14
4RZ (GB). **YARNOLD, Christopher John**; 114 Innova-
tion Drive, Milton Park, Abingdon Oxfordshire OX14 4RZ
(GB).

(74) Agent: **BRODOWSKI, Michael**; Goodwin Procter LLP,
100 Northern Avenue, IP DOCKETING DEPT./7TH FL,
Boston, Massachusetts 02210 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE



(57) Abstract: The present disclosure provides, in part, compounds of formula (I), or a stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein; pharmaceutical compositions comprising the compounds; and methods of using the compounds to treat conditions, diseases, and disorders associated with aberrant levels of lipids.

WO 2023/215220 A1